-Advertisement-
-Advertisement-
Oncology
Ripretinib appears safe, effective in KIT-altered metastatic melanoma
Ripretinib, a broad-spectrum KIT and platelet-derived growth factor receptor A switch-control tyrosine kinase inhibitor, was found to be safe and effective in patients with KIT-altered metastatic melanoma, according to trial results. In this study, 26 patients with KIT-altered metastatic melanoma were treated with 150 mg once daily ripretinib in 28-day...
Read More By rd360stg
By rd360stg
-Advertisement-
-Advertisement-
-Advertisement=-
By rd360stg
By rd360stg
-Advertisement-
-Advertisement-
-Advertisement=-
By rd360stg
By rd360stg
-Advertisement-
-Advertisement-
-Advertisement-

Stay Connected! Join Our Newsletter
Contact
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809
+908-505-8899
info@ihmholdings.com
QUICK LINKS
© 2022 IHM. RD 360 is a trademark of International Healthcare Media, LLC. All rights Reserved